{"id":"W3134598999","doi":"10.1200/jco.2021.39.6_suppl.tps506","title":"SURE: An open label, sequential-arm, phase II study of neoadjuvant sacituzumab govitecan (SG), and SG plus pembrolizumab (pembro) before radical cystectomy, for patients with muscle-invasive bladder cancer (MIBC) who cannot receive or refuse cisplatin-based chemotherapy.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Genome British Columbia","funders":"","keywords":"Medicine; Pembrolizumab; Cystectomy; Tolerability; Bladder cancer; Irinotecan; Oncology; Internal medicine; Cisplatin; Durvalumab; Clinical trial; Chemotherapy; Urology; Cancer; Surgery; Adverse effect; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001718113,0.001947661,0.001962184,0.0005450828,0.0003238703,0.001151708,0.001353451,0.00192651,0.007931283],"category_scores_gemma":[0.001105984,0.0009329768,0.001529076,0.0004222305,0.001574245,0.002052939,0.0006657328,0.003609752,0.001707154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007745505,"about_ca_system_score_gemma":0.001208586,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005430024,"about_ca_topic_score_gemma":0.002270064,"domain_scores_codex":[0.9995241,0.000220835,0.00001976252,0.0001045183,0.00004292573,0.00008781729],"domain_scores_gemma":[0.9992151,0.0001404673,0.0001642177,0.00008364071,0.00003660562,0.0003599519],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8493387,0.07122943,0.001968723,0.001014713,0.001160387,0.0001320957,0.0002767218,0.002598405,0.02690778,0.0004950537,0.004081411,0.0407966],"study_design_scores_gemma":[0.6101873,0.3805052,0.003477854,0.00003034302,0.0003458372,0.0001596135,0.00006319483,0.001002493,0.001654185,0.0002823049,0.002258688,0.00003306945],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883272,0.001897807,0.0007405556,0.000587087,0.0002624971,0.003252016,0.0019366,0.0002138974,0.002782247],"genre_scores_gemma":[0.9749078,0.002362542,0.002606764,0.002113466,0.0003451731,0.00536653,0.004738158,0.00008930536,0.007470244],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007931283,"threshold_uncertainty_score":0.02653283,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1177163740229022,"score_gpt":0.4654689810699678,"score_spread":0.3477526070470656,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}